middle.news
Chimeric’s CHM CDH17 Scores FDA Fast Track for Tough GI Tumours
9:56am on Wednesday 4th of June, 2025 AEST
•
Healthcare
Read Story
Chimeric’s CHM CDH17 Scores FDA Fast Track for Tough GI Tumours
9:56am on Wednesday 4th of June, 2025 AEST
Key Points
FDA grants Fast Track designation to CHM CDH17 for GEP-NETs
Phase 1/2 trial underway with 5 patients treated and 7 manufacturing runs completed
CHM CDH17 targets CDH17 biomarker linked to poor prognosis in GI cancers
Fast Track status enables more frequent FDA interactions and potential accelerated approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE